Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Head and neck cancer, excluding thyroid

1666 - Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Date

11 Sep 2017

Session

Head and neck cancer, excluding thyroid

Presenters

Ezra Cohen

Citation

Annals of Oncology (2017) 28 (suppl_5): v605-v649. 10.1093/annonc/mdx440

Authors

E.E. Cohen1, K.J. Harrington2, C. Le Tourneau3, J. Dinis4, L. Licitra5, M. Ahn6, A. Soria7, J. Machiels8, N. Mach9, R. Mehra10, B. Burtness11, Y. Wang12, A.J. Tuozzo12, R. Swaby13, D. Soulieres14

Author affiliations

  • 1 Medicine, University of California, San Diego Moores Cancer Center, 92093 - La Jolla/US
  • 2 Head Of Division Of Radiotherapy And Imaging, Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, London/GB
  • 3 Dept Of Medical Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 4 Medical Oncology, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), 4200-072 - Porto/PT
  • 5 Head And Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, 20133 - Milan/IT
  • 6 Division Of Hematology/oncology, Department Of Medicine, Samsung Medical Center, Seoul/KR
  • 7 Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid/ES
  • 8 Oncology, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 9 Clinical Research Unit/oncology, Hôpitaux Universitaires de Genève, 1211 - Geneva/CH
  • 10 Oncology, Fox Chase Cancer Center, Philadelphia/US
  • 11 Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven/US
  • 12 Biostatistics And Research Design Sciences, Merck & Co., Inc., Kenilworth/US
  • 13 Oncology Clinical Development, Merck & Co., Inc., Kenilworth/US
  • 14 Medicine, Service Of Hematology-oncology, CHUM, Montreal/CA
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1666

Background

Pembro showed antitumor activity and manageable toxicity in R/M HNSCC in an extended phase 1b study. KEYNOTE-040 (NCT02252042) was a global, open-label, phase 3 study of pembro vs SOC for R/M HNSCC.

Methods

Eligible pts with SCC of the oral cavity, oropharynx, hypopharynx, or larynx who had recurrence or PD after a platinum-containing regimen were randomized 1:1 to pembro 200 mg Q3W for 24 mo or investigator choice of standard doses of methotrexate (M), docetaxel (D), or cetuximab (C). Randomization was stratified by ECOG PS (0 vs 1), HPV status (p16 positive vs negative), and PD-L1 tumor proportion score (TPS) (≥50% vs 

Results

495 pts enrolled: 247 were assigned to pembro, 248 to SOC (65 M, 110 D, 73 C). After median follow-up of 7.3 mo, 8.9% of pts remained on pembro, 0.9% on SOC. Pembro prolonged OS in the ITT population, but the difference did not achieve statistical significance (HR 0.81, one-sided P = .0204; Table). There was no difference in PFS (Table). ORR was higher with pembro (Table). Pembro outcomes were improved in pts with PD-L1–expressing tumors (Table). 12.5% of pts in the SOC arm received subsequent immunotherapy, potentially impacting OS. Grade 3-5 drug-related AE incidence was 13.4% with pembro and 36.3% with SOC; 1.6% and 0.9%, respectively, died of drug-related AEs.

Table:

LBA45_PR OS, PFS, and ORR in KEYNOTE-040

TotalPD-L1 CPS ≥1%PD-L1 TPS ≥50%
PembroSOCPembroSOCPembroSOC
N = 247N = 248n = 196n = 191n = 64n = 65
OS
Median (95% CI), mo8.47.18.77.111.67.9
(6.5-9.4)(5.9-8.1)(6.9-11.4)(5.7-8.6)(8.3-19.5)(4.8-9.3)
HRa (95% CI)0.81 (0.66-0.99)0.75 (0.59-0.95)0.54 (0.35-0.82)
Pa.0204.0078b.0017b
PFSc
Median (95% CI), mo2.12.32.22.33.52.2
(2.1-2.3)(2.1-2.8)(2.1-3.0)(2.1-3.3)(2.1-6.3)(2.0-2.5)
HRa (95% CI)0.95 (0.79-1.16)0.89 (0.72-1.11)0.58 (0.39-0.87)
Pa.3037b.1526b.0034b
ORR,c %14.610.117.39.926.69.2
Pa.0610b.0171b.0009b
a

One-sided P value stratified by the randomization stratification factors.

b

Nominal only.

c

Assessed per RECIST v1.1 by blinded, independent central review.

Conclusions

Pembro provided an 19% reduction in the risk of death over SOC in pts with R/M HNSCC, although the prespecified efficacy boundary was not reached; subsequent immunotherapy in the SOC arm may have confounded OS analysis. Greater differences in OS, PFS, and ORR favoring pembro were seen in patients with PD-L1 expressing tumors.

Clinical trial identification

ClinicalTrials.gov number NCT02252042, originally posted Sep 25, 2014; EudraCT number 2014-001749-26, originally issued 1-Aug-2014

Legal entity responsible for the study

Merck & Co., Inc.

Funding

Merck & Co., Inc.

Disclosure

E.E. Cohen: Advisory board member for Human Longevity Inc., Merck, and CARsgen Therapeutics. Receiving honoraria from Merck, Pfizer, Celgene, AstraZeneca, Bristol-Myers Squibb, Merck Serono, Amgen, Apexigen, and Vigilant Biosciences. K.J. Harrington: Advisory board member, speakers\' bureau, and honoraria: MSD, AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer Research funding: MSD, AstraZeneca. C. Le Tourneau: Advisory board: MSD, AstraZeneca, Bristol-Myers Squibb, Amgen. Honoraria: Merck Serono, AstraZeneca, Bristol-Myers Squibb. Travel expenses: Bristol-Myers Squibb, MSD, Merck Serono. J. Dinis: Advisory board: Roche, PharmaMar, Bristol-Myers Squibb, Merck Serono. Research funding: Boehringer Ingelheim. Honoraria: Bristol-Myers Squibb, Merck Serono. Travel expenses: Bristol-Myers Squibb, PharmaMar. L. Licitra: Consulting or advisory role: Eisai, Bristol-Myers Squibb, MSD, Merck-Serono, Boehringer Ingelheim, Debiopharm, Jobi, Novartis, AstraZeneca, Bayer, Roche, Amgen, DOBI. Travel: Merck-Serono, Debiopharm, DOBI, Bayer, Amgen. M-J. Ahn: Advisory board member and honoraria: AstraZeneca, Merck, Lilly, Bristol-Myers Squibb, Roche A. Soria: Advisory board: Bristol-Myers Squibb, Roche, Novartis, Incyte. Speakers\' bureau: Roche, Novartis, MSD, Bristol-Myers Squibb. Travel: Roche, MSD, Bristol-Myers Squibb. J-P. Machiels: Advisory board: MSD (uncompensated), AstraZeneca, Debio, Nonbiotix, Innate. Research funding: Novartis, Bayer, Janssen. N. Mach: Advisory board: MSD, Bristol-Myers Squibb, Amgen. Honoraria: Bristol-Myers Squibb R. Mehra: Consulting: Genentech. B. Burtness: Advisory board member: Merck, Boehringer Ingelheim, AstraZeneca, Amgen Research funding (to institution): Merck, Advaxis, Bristol-Myers Squibb. Travel expenses: Boehringer Ingelheim. Y. Wang, A.J. Tuozzo, R. Swaby: Employment and stock ownership: Merck & Co., Inc. D. Soulieres: Advisory board member and research funding: Merck & Co.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings